Drugs for Diabetes: Part 8 SGLT2 Inhibitors

Alison MacEwen; Gerard A McKay; Miles Fisher


Br J Cardiol. 2012;19(1):26-29. 

In This Article


SGLT2 inhibitors offer a novel insulin-independent approach for the control of hyperglycaemia without incurring hypoglycaemia. Their efficacy is not affected by the extent of insulin resistance or beta-cell dysfunction and, therefore, in principle, they can be used at any stage in the natural history of type 2 diabetes. Initial studies suggest they can be used as monotherapy or in combination with insulin or metformin. Treatment is associated with mean weight loss and a small reduction in blood pressure, which may also be beneficial to patients with co-existing cardiovascular disease. Further trials regarding long-term cardiovascular outcomes are ongoing.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: